Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 May;107(5):1247-1260.
doi: 10.1016/j.xphs.2018.01.007. Epub 2018 Jan 11.

Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins

Michael R Turner  1 , Sathy V Balu-Iyer  2
Affiliations
Review

Challenges and Opportunities for the Subcutaneous Delivery of Therapeutic Proteins

Michael R Turner et al. J Pharm Sci. 2018 May.

Abstract

Biotherapeutics is a rapidly growing drug class, and over 200 biotherapeutics have already obtained approval, with about 50 of these being approved in 2015 and 2016 alone. Several hundred protein therapeutic products are still in the pipeline, including interesting new approaches to treatment. Owing to patients' convenience of at home administration and reduced number of hospital visits as well as the reduction in treatment costs, subcutaneous (SC) administration of biologics is of increasing interest. Although several avenues for treatment using biotherapeutics are being explored, there is still a sufficient gap in knowledge regarding the interplay of formulation conditions, immunogenicity, and pharmacokinetics (PK) of the absorption of these compounds when they are given SC. This review seeks to highlight the major concerns and important factors governing this route of administration and suggest a holistic approach for effective SC delivery.

Keywords: absorption; bioavailability; biotechnology; formulation; immune response; pharmacokinetics; physicochemical properties; proteins.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Figure 2
Figure 2
See this image and copyright information in PMC

References

    1. Biopharma. BIOPHARMA: Biopharmaceutical Products in the U.S. and European Markets U.S. Approvals, 2002-present. 2017.
    1. Jin J-f, Zhu L-l, Chen M, Xu H-m, Wang H-f, Feng X-q, Zhu X-p, Zhou Q. The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient preference and adherence. 2015;9:923–942. - PMC - PubMed
    1. Rule S, Collins GP, Samanta K. Subcutaneous vs intravenous rituximab in patients with non- Hodgkin lymphoma: a time and motion study in the United Kingdom. Journal of medical economics. 2014;17(7):459–468. - PubMed
    1. Sanford M. Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer. Targeted oncology. 2014;9(1):85–94. - PubMed
    1. Ashai NI, Paganini EP, Wilson JM. Intravenous versus subcutaneous dosing of epoetin: a review of the literature. American journal of kidney diseases : the official journal of the National Kidney Foundation. 1993;22(2 Suppl 1):23–31. - PubMed

Table References

    1. Food and Drug Administration Approval Information. Adalimumab Product Approval Information – Licensing Action 12/31/02. 2002
    1. Food and Drug Administration Approval Information. Infliximab Product Approval Information - Licensing Action 11/10/99. 1999
    1. Food and Drug Administration Approval Information. RITUXAN HYCELA™ (rituximab and hyaluronidase human) injection, for subcutaneous use. 2017
    1. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis and rheumatism. 2006;54(5):1390–1400. - PubMed
    1. Denoel A, Dieude P, Chollet-Martin S, Grootenboer-Mignot S. SAT0181 Immunogenicity of Rituximab in Patients with Rheumatoid Arthritis: A Kinetic Analysis. Annals of the rheumatic diseases. 2015;74(Suppl 2):720–720.

Publication types

MeSH terms